ADMA Biologics Inc
NASDAQ:ADMA
ADMA Biologics Inc
Total Assets
ADMA Biologics Inc
Total Assets Peer Comparison
Competitive Total Assets Analysis
Latest Figures & CAGR of Competitors
Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADMA Biologics Inc
NASDAQ:ADMA
|
Total Assets
$350.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
35%
|
CAGR 10-Years
27%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$148.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$56.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$93B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$23.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
27%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$34.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
27%
|
See Also
What is ADMA Biologics Inc's Total Assets?
Total Assets
350.9m
USD
Based on the financial report for Mar 31, 2024, ADMA Biologics Inc's Total Assets amounts to 350.9m USD.
What is ADMA Biologics Inc's Total Assets growth rate?
Total Assets CAGR 10Y
27%
Over the last year, the Total Assets growth was 3%. The average annual Total Assets growth rates for ADMA Biologics Inc have been 14% over the past three years , 35% over the past five years , and 27% over the past ten years .